| Patient groups | p-values | |||
---|---|---|---|---|---|
(A) Anti-GM2 + | (B) Anti-GM1+ | (C) Anti-GM2/GM1- | A vs. B | A vs. C | |
N = 13 | N = 63 | N = 48 | |||
IgM anti-GM1 IgM positive (n (%)) | 9 (69) | 63 (100) | 0 (0) | - | - |
IgM anti-GM2 IgM positive (n (%)) | 13 (100) | 0 (0) | 0 (0) | - | - |
Male sex (n (%)) | 10 (77) | 47 (75) | 36 (75) | 1.00 | 1.00 |
EFNS MMN diagnosis (n (%)) | Â | Â | Â | 0.88 | 0.54 |
 Definite | 10 (77) | 42 (67) | 36 (77) |  |  |
 Probable | 3 (23) | 16 (25) | 7 (15) |  |  |
 Possible | 0 (0) | 5 (8) | 4 (8) |  |  |
Age at onset (median years (IQR)) | 31 (16) | 43 (13) | 42 (14) | 0.015* | 0.034* |
Inclusion MAIN 2007 (n (%)) | 12 (92) | 50 (79) | 25 (52) | - | - |
Inclusion MAIN 2015 (n (%)) | 10 (77) | 43 (68) | 41 (85) | - | - |
Inclusion MAIN 2007 & MAIN 2015 (n (%)) | 9 (69) | 30 (47) | 20 (42) | - | - |
Disease duration (median months (IQR)) | Â | Â | Â | Â | Â |
 At first UMCU visit | 57 (96) | 49 (80) | 32 (63) | 0.36 | 0.037* |
 MAIN 2007 | 216 (120) | 132 (141) | 120 (96) | 0.13 | 0.042* |
 MAIN 2015 | 308 (170) | 216 (182) | 166 (122) | 0.16 | 0.008* |
Nerve conduction studies at diagnosis | Â | Â | Â | Â | Â |
 Conduction block (n (%)) | 12 (93) | 50 (93) | 43 (96) | 1.00 | 0.54 |
 Definite conduction block (n (%)) | 9 (69) | 34 (63) | 36 (80) | 0.76 | 0.46 |
 Axonal damage (n (%)) | 7 (54) | 24 (44) | 13 (29) | 0.55 | 0.11 |
 Nerves with CB (median (range)) | 2 (0–9) | 3 (0–12) | 3 (0–14) | 0.94 | 0.90 |
 Nerves with definite CB (median (range)) | 1 (0–5) | 1 (0–5) | 1 (0–8) | 0.68 | 0.84 |
 Nerves with axonal damage (median (range)) | 1 (0–7) | 0 (0–7) | 0 (0–3) | 0.73 | 0.31 |
IVIg treatment (n (%)) | Â | Â | Â | Â | Â |
 At first UMCU visit | 5 (42) | 16 (25) | 4 (9) | 0.30 | 0.015* |
 MAIN 2007 | 10 (83) | 39 (78) | 17 (68) | 1.00 | 0.44 |
 MAIN 2015 | 10 (100) | 39 (91) | 15 (75) | 1.00 | 0.14 |
IVIg dosage (median gr/month (IQR)) | Â | Â | Â | Â | Â |
 MAIN 2007 | 18 (9) | 14 (8) | 12 (7) | 0.33 | 0.16 |
 MAIN 2015 | 20 (8) | 15 (10) | 10 (7) | 0.85 | 0.08 |
Monoclonal gammopathy (n (%)) | Â | Â | Â | Â | Â |
 IgM | 1 (8) | 6 (10) | 3 (7) | 1.00 | 1.00 |
 IgG | 0 (0) | 2 (3) | 2 (5) | 1.00 | 1.00 |
CSF studies performed (n (%)) | 2 (15) | 15 (26) | 15 (31) | 0.72 | 0.48 |
 CSF elevated protein level | 2 (100) | 15 (100) | 9 (60) | 1.00 | 0.51 |
 CSF leukocytosis | 0 (0) | 0 (0) | 1 (14) | - | - |
Brachial plexus MRI abnormalities (n (%)) | 7 (78) | 17 (45) | 10 (33) | 0.14 | 0.026* |
MRC sum score (median (IQR)) | Â | Â | Â | Â | Â |
 At first UMCU visit | 115 (4) | 121 (9) | 124 (8) | 0.12 | 0.0003* |
 ΔMRCss (MAIN 2007–2015) | -8 (9) | -11 (10) | -4 (7) | 0.41 | 0.13 |
Postural tremor (n (%)) | 8 (80) | 27 (64) | 25 (63) | 0.47 | 0.46 |
Sensory abnormalities (n (%)) | Â | Â | Â | Â | Â |
 Hypesthesia/paresthesia | 4 (33) | 3 (6) | 4 (16) | 0.023* | 0.39 |
 Vibration sense abnormalities | 3 (25) | 13 (26) | 3 (12) | 1.00 | 0.37 |